Zifi-AZ Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Azithromycin 250 mg, indicated for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, effective against various gram-positive and gram-negative pathogens. Azithromycin, a macrolide antibiotic, impedes bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby exhibiting a broad spectrum of activity against atypical and intracellular organisms. The synergistic action of these two agents enhances efficacy in treating respiratory tract infections, urinary tract infections, skin and soft tissue infections, and certain sexually transmitted infections. Zifi-AZ Tablet is particularly useful in cases where mixed infections or resistant strains are suspected. The recommended dosage and duration should be strictly adhered to, as per clinical guidelines, to minimize resistance development. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypersensitivity reactions, though rare, warrant immediate medical attention. Caution is advised in patients with a history of hypersensitivity to cephalosporins or macrolides, and dose adjustments may be necessary in renal impairment. Zifi-AZ Tablet should be prescribed by a qualified healthcare professional following appropriate diagnostic evaluation.